OpenAI researcher Miles Wang leaves to launch AI drug‑discovery startup, seeks $200 million funding

Key Points

• Miles Wang, an OpenAI researcher, is leaving to start an AI drug‑discovery company.
• The startup is reportedly seeking about $200 million in funding at a $2 billion valuation.
• Lightspeed Venture Partners is in talks to lead the financing round.
• Wang disputes the reported funding figures, but details remain confidential.
• The venture aims to use AI to repurpose FDA‑approved drugs and revive failed candidates.
• Recent AI‑biotech deals include $400 million for Chai Discovery and $2.1 billion for Isomorphic Labs.
• Wang joined OpenAI after dropping out of Harvard and has co‑authored research on AI‑driven scientific discovery.